Artivion presented new clinical data from its NEXUS TRIOMPHE and AMDS PERSEVERE trials at the 62nd Society of Thoracic Surgeons Annual Meeting in New Orleans on February 2, 2026.
The NEXUS TRIOMPHE IDE trial enrolled 94 high‑risk patients (40% ASA class III and 57% ASA class IV). One‑year results showed 94 % survival from lesion‑related death, 91 % freedom from disabling stroke, and 97 % freedom from reintervention due to endoleaks. The study also reported a single case of paraplegia and no renal failure, underscoring the device’s safety profile and supporting Artivion’s regulatory strategy in the aortic arch market.
The AMDS PERSEVERE IDE trial included 93 participants. Two‑year data revealed zero distal anastomotic new entry tears, sustained aortic remodeling, and stable total aortic diameter changes of less than 2 mm across zones 1‑6. Four deaths from unrelated causes were recorded, and the reoperation rate remained at 4.3 % with no additional unanticipated aortic reoperations, reinforcing the safety and durability of the AMDS Hybrid Prosthesis.
Artivion’s strategy is to capture a $150 million U.S. opportunity for chronic arch disease and to expand its AMDS platform for acute Type A dissections. The company holds exclusive distribution rights for NEXUS in Europe, and the global aortic arch market is estimated at $600‑$800 million. The NEXUS IDE data will be incorporated into a PMA filing expected after one year of follow‑up, while the AMDS device, granted a Humanitarian Device Exemption in December 2024, is slated for full PMA approval by mid‑2026.
Management highlighted the clinical success, with CEO Pat Mackin noting that the outcomes validate Artivion’s therapeutic options for patients with aortic arch disease. The company’s financial trajectory remains mixed, with revenue growth steady but profitability still a work in progress; analysts anticipate a near‑term turnaround as regulatory approvals materialize.
No immediate market reaction data were available, but the clinical results are expected to accelerate adoption and support future pricing and reimbursement discussions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.